当前位置: 首页 >> 检索结果
902. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group.
作者: J G McHutchison.;T Poynard.;S Pianko.;S C Gordon.;A E Reid.;J Dienstag.;T Morgan.;R Yao.;J Albrecht.
来源: Gastroenterology. 2000年119卷5期1317-23页
Black patients with chronic hepatitis C have lower response rates than white patients to interferon monotherapy. The factors responsible for these differences are unknown, as is the impact of combination antiviral therapy on responsiveness among ethnic groups. We evaluated the impact of race on response to therapy in these patients.
903. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis.
作者: J Panés.;M Esteve.;E Cabré.;J Hinojosa.;M Andreu.;M Sans.;F Fernandez-Bañares.;F Feu.;M A Gassull.;J M Piqué.
来源: Gastroenterology. 2000年119卷4期903-8页
Unfractionated heparin has been found to reduce symptoms and improve healing as adjuvant therapy in patients with ulcerative colitis. The current study evaluated the efficacy and safety of unfractionated heparin in the treatment of ulcerative colitis in comparison with methylprednisolone.
904. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.
Clinical experience suggests that 6-mercaptopurine (6-MP) is effective therapy for children with active steroid-dependent Crohn's disease (CD). We report the results of a prospective, placebo-controlled, multicenter trial evaluating the combination of 6-MP and prednisone as therapy for children with newly diagnosed moderate-to-severe CD.
905. A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia.
作者: J Hamilton.;E Guthrie.;F Creed.;D Thompson.;B Tomenson.;R Bennett.;K Moriarty.;W Stephens.;R Liston.
来源: Gastroenterology. 2000年119卷3期661-9页
This study aimed to determine whether brief psychodynamic-interpersonal (PI) psychotherapy is more efficacious than a psychological control for patients with chronic, intractable functional dyspepsia (FD), and whether patients with abnormal gastric function respond differently than those with normal gastric function.
906. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease.
Low bone mineral density (BMD) is a common complication of Crohn's disease and may lead to increased morbidity and mortality because of fractures. We investigated the effect of treatment with the bisphosphonate alendronate on bone mass and markers of bone remodeling in patients with Crohn's disease.
907. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women.
作者: F L Lanza.;R H Hunt.;A B Thomson.;J M Provenza.;M A Blank.
来源: Gastroenterology. 2000年119卷3期631-8页
Bisphosphonates are effective treatment for osteoporosis, but upper gastrointestinal injury associated with some compounds has caused concern. This study compared the incidence of gastric ulcers after treatment with risedronate, a pyridinyl bisphosphonate, and alendronate, a primary amino bisphosphonate. Esophageal and gastroduodenal injury assessed by endoscopy scores was a secondary endpoint.
908. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.
作者: P Gionchetti.;F Rizzello.;A Venturi.;P Brigidi.;D Matteuzzi.;G Bazzocchi.;G Poggioli.;M Miglioli.;M Campieri.
来源: Gastroenterology. 2000年119卷2期305-9页
Pouchitis is the major long-term complication after ileal pouch-anal anastomosis for ulcerative colitis. Most patients have relapsing disease, and no maintenance treatment study has been performed. We evaluated the efficacy of a probiotic preparation (VSL#3) containing 5 x 10(11) per gram of viable lyophilized bacteria of 4 strains of lactobacilli, 3 strains of bifidobacteria, and 1 strain of Streptococcus salivarius subsp. thermophilus compared with placebo in maintenance of remission of chronic pouchitis.
909. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
作者: Y F Liaw.;N W Leung.;T T Chang.;R Guan.;D I Tai.;K Y Ng.;R N Chien.;J Dent.;L Roman.;S Edmundson.;C L Lai.
来源: Gastroenterology. 2000年119卷1期172-80页
One-year lamivudine therapy significantly suppressed hepatitis B virus (HBV) replication, improved hepatic necroinflammatory activity, and prevented progression of fibrosis. However, the effects of prolonged therapy are unknown.
910. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans.
作者: B Coulie.;L A Szarka.;M Camilleri.;D D Burton.;S McKinzie.;N Stambler.;J M Cedarbaum.
来源: Gastroenterology. 2000年119卷1期41-50页
The aim of this study was to assess the effects of recombinant human brain-derived neurotrophic factor (r-metHuBDNF) and recombinant human neurotrophic factor 3 (r-metHuNT-3) on gastrointestinal motor functions in healthy people and in patients with constipation.
911. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study.
作者: J J Sung.;S R Lin.;J Y Ching.;L Y Zhou.;K F To.;R T Wang.;W K Leung.;E K Ng.;J Y Lau.;Y T Lee.;C K Yeung.;W Chao.;S C Chung.
来源: Gastroenterology. 2000年119卷1期7-14页
Helicobacter pylori-infected gastric mucosa evolves through stages of chronic gastritis, intestinal metaplasia (IM), glandular atrophy (GA), and dysplasia before carcinoma develops. We studied if H. pylori eradication would alter the course of premalignant histologic changes in the stomach.
912. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders.
Interleukin (IL)-10 is a cytokine that down-regulates the proinflammatory response and has a modulatory effect on hepatic fibrogenesis. The aim of this study was to determine the effect of IL-10 on hepatic injury in patients with chronic hepatitis C.
915. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.
作者: C M Prather.;M Camilleri.;A R Zinsmeister.;S McKinzie.;G Thomforde.
来源: Gastroenterology. 2000年118卷3期463-8页
This study evaluated the effects of a partial 5-hydroxytryptamine (5-HT)(4) agonist, tegaserod, on gastric small bowel and colonic transit in constipation-predominant irritable bowel syndrome (IBS).
916. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.
作者: H Lochs.;M Mayer.;W E Fleig.;P B Mortensen.;P Bauer.;D Genser.;W Petritsch.;M Raithel.;R Hoffmann.;V Gross.;M Plauth.;M Staun.;L B Nesje.
来源: Gastroenterology. 2000年118卷2期264-73页
This study investigated if long-term treatment with high-dose mesalamine reduces the risk of clinical relapse of Crohn's disease after surgical resection.
917. Effects of sildenafil on esophageal motility of patients with idiopathic achalasia.
作者: M Bortolotti.;C Mari.;C Lopilato.;G Porrazzo.;M Miglioli.
来源: Gastroenterology. 2000年118卷2期253-7页
Sildenafil shows an intense and prolonged inhibitory effect on the smooth muscle cells of the human corpus cavernosum by blocking phosphodiesterase type 5 that destroys nitric oxide-stimulated cyclic guanosine monophosphate. We investigated if sildenafil possesses a similar effect on the esophageal musculature of patients with achalasia, where there is an impairment of nitric oxide production similar to that of functional impotence.
918. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects.
Transient lower esophageal sphincter (LES) relaxations are the major mechanism of gastroesophageal reflux in normal subjects and in most patients with reflux disease. gamma-Aminobutyric acid (GABA) is an important inhibitory neurotransmitter within the central nervous system which is present in regions of the brainstem that are believed to mediate transient LES relaxations. The aim of this study was to investigate the effect of a GABA(B) agonist baclofen on postprandial gastroesophageal reflux and transient LES relaxations.
920. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis.
作者: M M Kaplan.;C Schmid.;D Provenzale.;A Sharma.;G Dickstein.;A McKusick.
来源: Gastroenterology. 1999年117卷5期1173-80页
The aim of this study was to determine if colchicine or methotrexate improves blood test results, symptoms, and/or liver histology in patients with primary biliary cirrhosis.
|